Navigation Links
Halozyme Begins Randomized, Controlled Clinical Trial with PEGPH20 in Patients with Advanced Pancreatic Cancer
Date:10/5/2011

obally. The primary endpoint of the Phase 2 portion of the trial is overall survival (OS). The trial will also evaluate secondary endpoints such as CA19-9, objective response rate and duration of response. CA19-9 is a tumor marker tested from blood samples in patients with pancreatic cancer.

About PEGPH20

PEGPH20 is a PEGylated form of rHuPH20 modified to allow it to survive in the blood stream.  PEGPH20 degrades hyaluronan (HA) which is a gel-like component found in tissues throughout the body. Certain solid tumor types (e.g. colon, breast, pancreatic and prostate cancers) have been shown to accumulate high levels of HA which creates a protective network surrounding the tumor cell. By degrading the HA, PEGPH20 may increase the accessibility of tumor cells to chemotherapeutic agents and improve the effectiveness of the treatment.

About Pancreatic Cancer

Pancreatic cancer is the fourth leading cause of cancer-related death in the United States. The National Cancer Institute estimates that in 2011 there will be more than 44,030 new cases of pancreatic cancer and 37,660 deaths from the disease.

About Halozyme

Halozyme Therapeutics is a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the insulin, cancer, dermatology and drug delivery markets. The company's product portfolio is based primarily on intellectual property covering the family of human enzymes known as hyaluronidases and additional enzymes that affect the extracellular matrix. Halozyme's Enhanze(TM) technology is a novel drug delivery platform designed to increase the absorption and dispersion of biologics. The company has key partnerships with Roche, Baxter, ViroPharma and Intrexon to apply Enhanze technology to therapeutic biologics including Herceptin®, MabThera®, immunoglobulin, Cinryze® and recombinant human alpha 1-antitrypsin. Halozyme's Ultrafa
'/>"/>

SOURCE Halozyme Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. ViroPharma and Halozyme Therapeutics Announce Initiation of Phase 2 Evaluation of Subcutaneous Delivery of Cinryze® (C1 Esterase Inhibitor [Human]) with Hyaluronidase (rHuPH20)
2. Halozyme Therapeutics to Present at Upcoming Financial Conferences
3. Halozyme Therapeutics to Present at the Wedbush 2011 Global Healthcare Conference on August 17
4. Halozymes Ultrafast Insulin Demonstrates Reduced Variability of Insulin Absorption for Type 1 Diabetes Patients Using Insulin Pumps
5. Halozyme and Intrexon Announce Collaboration to Develop First Subcutaneous Recombinant Alpha 1-Antitrypsin Replacement Therapy
6. Halozyme Therapeutics and ViroPharma Announce $83 Million Global Licensing Agreement to Develop Subcutaneous Cinryze® (C1 esterase inhibitor [human])
7. ViroPharma and Halozyme Announce Collaboration for Combination of Recombinant Human Hyaluronidase Enzyme (rHuPH20) Technology with C1 Esterase Inhibitor
8. Halozyme Therapeutics to Present at the Bank of America Merrill Lynch Health Care Conference on May 12
9. Halozyme Therapeutics to Host First Quarter 2011 Financial Results Conference Call on May 6
10. Halozyme Therapeutics Reports Fourth Quarter and Year End 2010 Financial Results
11. Halozyme Therapeutics to Host Fourth Quarter and 2010 Financial Results Conference Call on March 11
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... CHENGDU, China , Jan. 23, 2015 Tianyin ... pharmaceutical company that specializes in the development and sale ... branded generics and active pharmaceutical ingredients (API) today announced ... Facility (JCM) API operation. 1. Following the ...
(Date:1/22/2015)... 2015  ResMed Inc. (NYSE: RMD ) today announced ... the quarter was $423.0 million, a 10 percent increase compared ... increase on a constant currency basis). Net income was $91.2 ... ended December 31, 2013. Diluted earnings per share for the ...
(Date:1/22/2015)... 22, 2015  Profil Institute for Clinical Research, Inc., a ... announced today a new textbook,  Translational Research Methods for ... a leading global scientific publisher. The textbook ... for use in early phase clinical studies of new ...
Breaking Medicine Technology:TPI's JCM Updates on Import Registration for International Clients 2TPI's JCM Updates on Import Registration for International Clients 3TPI's JCM Updates on Import Registration for International Clients 4ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 2ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 3ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 4ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 5ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 6ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 7ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 8ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 9ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 10ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 11New Textbook "Translational Research Methods for Diabetes, Obesity and Cardiometabolic Drug Development" Provides Critical Review Of Current And Emerging Clinical Investigation Methods 2New Textbook "Translational Research Methods for Diabetes, Obesity and Cardiometabolic Drug Development" Provides Critical Review Of Current And Emerging Clinical Investigation Methods 3
... 4, 2011 Adherence to strict outcome requirements ... Services (CMS) has an adverse effect on liver ... than optimal conditions, according to researchers at Northwestern ... quality improvement initiatives aim to enhance post-transplant outcomes, ...
... OAKS, Calif. and NEW YORK, Nov. 5, 2011 Amgen ... PFE ) today announced results of the second and ... multi-center trial in patients with moderately active rheumatoid arthritis (RA) ... (LDA) or clinical remission on combination Enbrel® (etanercept) plus methotrexate ...
Cached Medicine Technology:Study Calls for Modification of CMS Conditions of Participation to Preserve Access to Life-Saving Liver Transplantations under Less than Optimal Conditions 2Treatment With Enbrel® (etanercept) Shows Significant and Sustained Clinical Benefits in Rheumatoid Arthritis (RA) Patients With Moderately Active Disease 2Treatment With Enbrel® (etanercept) Shows Significant and Sustained Clinical Benefits in Rheumatoid Arthritis (RA) Patients With Moderately Active Disease 3Treatment With Enbrel® (etanercept) Shows Significant and Sustained Clinical Benefits in Rheumatoid Arthritis (RA) Patients With Moderately Active Disease 4Treatment With Enbrel® (etanercept) Shows Significant and Sustained Clinical Benefits in Rheumatoid Arthritis (RA) Patients With Moderately Active Disease 5Treatment With Enbrel® (etanercept) Shows Significant and Sustained Clinical Benefits in Rheumatoid Arthritis (RA) Patients With Moderately Active Disease 6Treatment With Enbrel® (etanercept) Shows Significant and Sustained Clinical Benefits in Rheumatoid Arthritis (RA) Patients With Moderately Active Disease 7Treatment With Enbrel® (etanercept) Shows Significant and Sustained Clinical Benefits in Rheumatoid Arthritis (RA) Patients With Moderately Active Disease 8Treatment With Enbrel® (etanercept) Shows Significant and Sustained Clinical Benefits in Rheumatoid Arthritis (RA) Patients With Moderately Active Disease 9Treatment With Enbrel® (etanercept) Shows Significant and Sustained Clinical Benefits in Rheumatoid Arthritis (RA) Patients With Moderately Active Disease 10Treatment With Enbrel® (etanercept) Shows Significant and Sustained Clinical Benefits in Rheumatoid Arthritis (RA) Patients With Moderately Active Disease 11
(Date:1/22/2015)... 23, 2015 VogueQueen is a seasoned and ... and many designers are thrilled to have it lead the ... its new collection of prom dresses for the global market. ... the strategic vision and he focuses on continuing the goal ...
(Date:1/22/2015)... New York, New York (PRWEB) January 22, 2015 ... ( http://www.vaginalmeshlawsuit2015.com/ ) in the U.S. District Court, Southern District ... against C.R. Bard, Inc. in that proceeding’s first bellwether trial. ... defense request for a new trial after finding that C.R. ...
(Date:1/22/2015)... For over 20 years, Dr. David Cruz of Cruz ... has treated just about every type of injury that can result ... those same twenty-plus years, the team at Doctors on Liens ... best possible doctor. With the combined breadth of experience ...
(Date:1/22/2015)... (PRWEB) January 23, 2015 Recently, Weddingshe.com has ... catalog, and has announced its highest annual revenues in the ... on its popular glamorous wedding dresses. , According to the ... important wedding dress promotions for them in 2015. This point ...
(Date:1/22/2015)... New York, NY (PRWEB) January 22, 2015 ... component of overall health care gains momentum worldwide, Rev. ... York-based HealthCare Chaplaincy Network (HCCN), will be the ... advance spiritual care in Israel’s public health system. , The ...
Breaking Medicine News(10 mins):Health News:VogueQueen Unveils New Designs of Prom Dresses for 2015 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 4Health News:Industry Leading Chiropractor in Oceanside Joins the Doctors on Liens Network 2Health News:Weddingshe Announces A Special Offer On Its Popular Glamorous Wedding Dresses 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 3
... Zimmer Holdings, Inc.,(NYSE ZMH; SWX: ZMH), a leader in ... following upcoming investor,conferences:, -- March 18, 2008 -- ... Massachusetts, 8:00 a.m. Eastern Time -- March 19, ... Conference, Miami Beach, Florida, 8:30 a.m. Eastern Time, ...
... The Campaign to Strengthen,Human Services, which is committed ... human service providers, today unveiled its,campaign website, ... social importance that human services providers bring to,all ... on passing Senate 65, a bill that would,establish ...
... survival rates, but one expert urges caution , , ... or specialized hospitals improved survival time for ovarian cancer ... the researchers examined data on 8,621 ovarian cancer patients ... those women, 40 percent were treated in general hospitals, ...
... also help, at least for a while, study finds, , , ... loss are often dismal, but a new study finds that ... they,re able to keep off more weight. , The ... were more likely to maintain their weight loss than people ...
... Nearly 8,000 nurses,and other healthcare workers in Ohio saw ... California Nurses Association flooded the state,with hostile organizers and ... calls urging them to vote against the union., ... an affiliate of the,AFL-CIO, the workers have for now ...
... Theres new evidence supporting the idea that bigger brains are ... the brainpower required to be dominant drives brain capacity. , ... in the brains of both males and females of one ... were also associated with being dominant. The study also ...
Cached Medicine News:Health News:New Human Services Website Details Economic Importance of Providers, Warns of Looming Crisis if System is Not Fixed Immediately 2Health News:Specialized Care for Ovarian Cancer Improves Outcomes 2Health News:Personal Contact Helps Maintain Weight Loss 2Health News:Personal Contact Helps Maintain Weight Loss 3Health News:SEIU: Thousands of Ohio Nurses and Other Healthcare Employees Denied a Voice at Work After Vicious Union-Busting Campaign by the California Nurses Association 2Health News:Which came first, social dominance or big brains? Wasps may tell 2Health News:Which came first, social dominance or big brains? Wasps may tell 3
... is designed to comfortably restrict motion ... unobstructed motion of the fingers and ... the splint may be trimmed using ... heat gun. One cotton stockinet is ...
FREEDOM® Memory Thumb Spica lets you make a custom splint in minutes. Immerese in 160 F water until pliable, and remove. Amazingly, it maintains its shape and is ready to be precisely, profession...
... QuickCast® Cast-like splints Slip ... dryer, and QuickCast conforms to ... cools. Reheat to adjust and ... coated with a temperature-sensitive polymer ...
... strong, the ThumSaver CMC Short lessens symptoms of ... and/or MP joints of the thumb. The ThumSaver ... IP joint motion for function. Includes felt padding ... and for rest due to repetitive stress injuries. ...
Medicine Products: